Lineage Cell logo

Lineage Cell

Stock
Stock
Ticker: LCTX
LCTX

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Lineage Cell is $247.42M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Lineage Cell's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.184. EPS indicates the company's profitability on a per-share basis.
Currently, 7 analysts cover Lineage Cell's stock, with a consensus target price of $5.50. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Lineage Cell reported a revenue of $13.08M.
Lineage Cell's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$26.11M. EBITDA measures the company's overall financial performance.
Lineage Cell has a free cash flow of -$24.39M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Lineage Cell employs approximately 77 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Lineage Cell is 191.05M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$247.42M
EPS (TTM) 
-$0.184
Free Float 
191.05M
Revenue (TTM) 
$13.08M
EBITDA (TTM) 
-$26.11M
Free Cashflow (TTM) 
-$24.39M

Pricing

1D span
$0.982$0.984
52W span
$0.882$2.085

Analyst Ratings

The price target is $5.50 and the stock is covered by 7 analysts.

Buy

6

Hold

1

Sell

0

Information

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Employees
77
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
LCTX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin